Which company?
This is not Ozempic, Advil, or vitamin D…
It’s an entirely new class of medicine that could earn you an absolute FORTUNE.
Because not only can it make you smarter, make you stronger, and extend your life span by as much as 20 years…
It’s also the most profitable drug in human history…
Because it has the potential to generate $1 TRILLION by swiping market share from some of the most profitable disease treatments in the world, such as:
• $35 billion on treatment for alcoholism…
• $90 billion on PTSD…
• $150 billion on depression…
• $39 billion on smoking cessation…
• $40 billion on treatments for neurodegenerative diseases…
• $16.4 billion on diabetes treatments…
• $2.1 billion on anorexia treatments…
• And $635 billion on treatments for chronic pain.
In fact, this pill could redefine the boundaries of modern medicine…
Promising to not only enhance your cognitive and physical abilities, but also to revolutionize the pharmaceutical industry.
And the best part is that the American Medical Association (AMA) just approved insurance billing codes for EN-23…
Which means that the FDA could sign off on this pill within six months.
We’re on the cusp of EN-23 becoming a household name…
Offering unprecedented treatment efficacy across a spectrum of diseases and personal enhancements.
That’s why I want to make sure you not only get access to it yourself…
But also profit from the most disruptive drug the medical establishment has witnessed since Alexander Fleming discovered penicillin in 1928.
While penicillin has saved more than 200 million lives since first coming to market…
EN-23 could save even more.
Because EN-23 Is Turning
Traditional Medicine on Its Head
Especially when it comes to treating depression, anxiety, PTSD, and addiction.
See, traditional treatments only address one disease at a time…
They take a long time to work — and often have painful side effects…
They’re expensive…
And only 30% effective.
But EN-23 could potentially treat an almost endless number of diseases with 60%–100% effectiveness with just a single dose!
At this very moment, scientists around the world are studying EN-23 for the treatment of:
• Alzheimer’s…
• Diabetes…
• Epilepsy…
• Obesity…
• Autoimmune diseases…
• Arthritis…
• Chronic pain…
• PTSD…
• Insomnia…
• Parkinson’s…
• Erectile dysfunction…
• And Crohn’s disease.
The list goes on and on.
And that’s not all!
EN-23 also offers personal growth possibilities like mastering new languages, boosting fitness, and eradicating anxiety.
This truly unique medicine is throwing out the “playbook” for treating many chronic diseases and mental illnesses…
Which is why billionaires around the
world are staking their claims on
the companybehind this miraculous
pill now.
I’m talking about folks like Kevin O’Leary of Shark Tank, who invested $6 million into EN-23…
PayPal co-founder Peter Thiel, who raised $125 million in funding…
And even ChatGPT CEO Sam Altman, who invested a few million dollars as well.
As Kevin O’Leary puts it: “This could save lives, cure depression, help alcoholism, get people off opiods — why wouldn’t I want to be invested?”
Even Elon Musk has stated: “I’ve talked to many more people who were helped by [EN-23] than SSRIs and amphetamines.”
And when Mike Tyson let it slip that he had been using EN-23, he told reporters that he wished he had used it in his prime — as it would have made him a better fighter.
Only a fool would ignore the profit potential of such a medical revolution.
Again, EN-23 could replace over $1 trillion worth of treatment that’s on the market today…
And the FDA is about to approve the first EN-23 treatment within the next six months.
Maybe even sooner.
Once that happens, every trend chaser on Wall Street will be loading up on the stocks associated with EN-23…
And they’ll be paying a hefty premium for those stocks compared to what you can buy them for right now.
So there’s not a lot of time to waste.
I’m ready to hand over all of my research
on three companies set to soar with
EN-23’s market debut.
But my member services team just informed me that your Green Chip Stocks membership has expired.
I understand that life sometimes gets in the way and you might have forgotten to renew your membership. No worries.
I’ve struck a deal with my publisher to offer you a one-year membership for only $199.
That’s a hell of a deal considering new members pay as much as $499 for one year.
As a member, you enjoy the following benefits:
• Full access to my model portfolio: You’ll have constant access to my carefully calculated portfolio that’s full of clear buy, sell, and hold recommendations.
• Our private, members-only website: You’ll receive a login to our exclusive website. This is where you’ll get to read the special reports and bonus issues that are only available to our lifetime members.
• Premium member services: Whenever you call into our offices, you’ll get to speak to a representative right away who’s prepared to answer your most pressing questions. You won’t be put on hold. Our lifetime members are always at the front of the line.
• Event notifications: When it comes to our research trips, annual meetings, or members-only dinners, you’ll be the first to know and at the top of the guest list.
Now is your opportunity to build your wealth.
That’s why I struck this deal with my publisher just for you.
Take a few minutes right now to reactivate your Green Chip Stocks membership for our special price of $199.
Once your membership is active, I’ll send you all the information on these EN-23 companies we are buying now.
And you know you can count on the advice to be solid, researched, and timely.
I can’t keep this offer open for long.
Lock in this special membership rate to Green Chip Stocks right now!
Good investing,

Jeff Siegel
Investment Director, Green Chip Stocks
P.S. The FDA is about to approve a groundbreaking EN-23 pill, a revolutionary class of medicine that’s set to redefine your health and wealth. With the potential to boost cognitive and physical abilities, extend your life span, and disrupt billion-dollar markets, EN-23 is on the brink of becoming a household name. That’s why billionaires like Kevin O’Leary, Peter Thiel, and Sam Altman have already invested millions of dollars into this miracle pill — and you should too. There are three companies leading the charge in getting FDA approval, and you need to act now, before Wall Street jumps on board and the biggest gains are off the table. Click here for more details.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.